Point72 Hong Kong’s Travere Therapeutics TVTX Stock Holding History

Point72 Hong Kong’s Portfolio TVTX Stock Details TVTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-5,439	Closed	-$140K	–	2418
2022 Q1	$140K	Buy	5,439 +5,233	+2,540%	+$139K	﹤0.01%	1069
2021 Q4	$6K	Buy	+206	New	+$5.8K	﹤0.01%	1717
2021 Q3	–	Sell	-1,469	Closed	-$21K	–	2444
2021 Q2	$21K	Buy	+1,469	New	+$29K	﹤0.01%	1643
2019 Q1	–	Sell	-48	Closed	-$1K	–	1282
2018 Q4	$1K	Buy	+48	New	+$1.19K	﹤0.01%	819
2018 Q3	–	Sell	-547	Closed	-$15K	–	1176
2018 Q2	$15K	Buy	+547	New	+$14.6K	0.01%	615
2017 Q2	–	Sell	-30	Closed	-$1K	–	1034
2017 Q1	$1K	Sell	30 -547	-95%	-$10.7K	﹤0.01%	684
2016 Q4	$11K	Buy	+577	New	+$11.8K	0.01%	644

Other funds holding TVTX

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Point72 Hong Kong's TVTX Position: Q2 2022 in Review

Point72 Hong Kong sold out of Travere Therapeutics (TVTX) in Q2 2022, closing a stake of 5,439 shares — an estimated $140K sold.

Point72 Hong Kong first reported a position in TVTX in Q4 2016 and held it in 7 quarters. The position peaked at $140K in Q1 2022. 171 funds tracked by Wall St. Rank hold TVTX as of Q2 2022.

Point72 Hong Kong reported no remaining Travere Therapeutics position as of Q2 2022 after selling out during the quarter.
Point72 Hong Kong sold 5,439 Travere Therapeutics shares in Q2 2022, an estimated $140K.
Point72 Hong Kong first reported a position in Travere Therapeutics in Q4 2016 and held it in 7 quarters.
Point72 Hong Kong's Travere Therapeutics position peaked at $140K in Q1 2022.
171 funds tracked by Wall St. Rank held Travere Therapeutics as of Q2 2022.

Based on Point72 Hong Kong's 13F filing for Q2 2022, filed 15 Aug 2022.